Buy Rating for Bolt Biotherapeutics: Innovative Approach and Strong Financials Drive Positive Outlook
I'm PortAI, I can summarize articles.
Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating for Bolt Biotherapeutics, citing its innovative approach and strong financials. Bolt's lead asset, BDC-4182, shows superior anti-tumor activity. The company reported a narrower net loss for Q3 2025 and has a strong cash position. Risks include data delays and competitive pressures. Lake Street also reiterated a Buy rating with a $75 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments